{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T22:15:03Z","timestamp":1791238503554,"version":"4.1.0"},"reference-count":90,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T00:00:00Z","timestamp":1769731200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Gastroenterol."],"abstract":"<jats:p>Ulcerative colitis is a chronic inflammatory bowel disease with rising global prevalence. Despite therapeutic advances including biologic agents targeting tumor necrosis factor-alpha, integrins, and interleukin pathways, alongside Janus kinase inhibitors and sphingosine-1-phosphate receptor modulators, substantial unmet needs persist in moderate to severe disease. Current advanced therapies achieve clinical response rates of only 30-60% in trials, with approximately 20% of patients requiring hospitalization and 7% undergoing colectomy within five years of diagnosis. The therapeutic pipeline for moderate to severe ulcerative colitis currently encompasses over 100 investigational agents in Phase II and III clinical development. Emerging mechanisms include next-generation Janus kinase and tyrosine kinase 2 inhibitors with enhanced selectivity, novel cell trafficking modulators, advanced tumor necrosis factor-alpha inhibition strategies, and selective interleukin-23 pathway antagonists. Tumor necrosis factor-like ligand 1A pathway inhibitors demonstrate particularly robust efficacy in early trials, with clinical remission rates exceeding 25% compared to less than 2% for placebo. Additional promising approaches target immune checkpoint pathways, receptor-interacting protein kinase 1, and intracellular signaling cascades. innovative combination therapy approaches demonstrated to achieve superior response rates compared to monotherapy. The convergence of novel therapeutic targets, gut-selective compounds minimizing systemic immunosuppression, and biomarker-guided therapy selection represents a paradigm shift toward precision medicine. These advances hold genuine promise for transforming moderate to severe ulcerative colitis management.<\/jats:p>","DOI":"10.3389\/fgstr.2026.1747118","type":"journal-article","created":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T05:25:56Z","timestamp":1769750756000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Advancing therapeutic frontiers: a pipeline of novel drugs for UC management"],"prefix":"10.3389","volume":"5","author":[{"given":"Luisa","family":"Bertin","sequence":"first","affiliation":[{"name":"Gastroenterology Unit, Department of Surgery, Oncology and Gastroenterology, University of Padova","place":["Padova, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Massano","sequence":"additional","affiliation":[{"name":"Gastroenterology Unit, Department of Surgery, Oncology and Gastroenterology, University of Padova","place":["Padova, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Redavid","sequence":"additional","affiliation":[{"name":"Gastroenterology Unit, Department of Surgery, Oncology and Gastroenterology, University of Padova","place":["Padova, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Scarpa","sequence":"additional","affiliation":[{"name":"Chirurgia Generale 3 Unit, Azienda Ospedale Universit\u00e0 di Padova","place":["Padua, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cesare","family":"Ruffolo","sequence":"additional","affiliation":[{"name":"Chirurgia Generale 3 Unit, Azienda Ospedale Universit\u00e0 di Padova","place":["Padua, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imerio","family":"Angriman","sequence":"additional","affiliation":[{"name":"Chirurgia Generale 3 Unit, Azienda Ospedale Universit\u00e0 di Padova","place":["Padua, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Buda","sequence":"additional","affiliation":[{"name":"Gastroenterology Unit, Department of Oncological Gastrointestinal Surgery, S. Maria del Prato Hospital","place":["Feltre, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabiana","family":"Zingone","sequence":"additional","affiliation":[{"name":"Gastroenterology Unit, Department of Surgery, Oncology and Gastroenterology, University of Padova","place":["Padova, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigida","family":"Barberio","sequence":"additional","affiliation":[{"name":"Gastroenterology Unit, Department of Surgery, Oncology and Gastroenterology, University of Padova","place":["Padova, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edoardo Vincenzo","family":"Savarino","sequence":"additional","affiliation":[{"name":"Gastroenterology Unit, Department of Surgery, Oncology and Gastroenterology, University of Padova","place":["Padova, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.15389","article-title":"Ulcerative colitis in adults: A review","volume":"330","author":"Gros","year":"2023","journal-title":"JAMA"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)32126-2","article-title":"Ulcerative colitis","volume":"389","author":"Ungaro","year":"2017","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1053\/j.gastro.2016.10.020","article-title":"Understanding and preventing the global increase of inflammatory bowel disease","volume":"152","author":"Kaplan","year":"2017","journal-title":"Gastroenterology"},{"key":"B4","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1038\/s41598-020-57460-6","article-title":"Sleep disturbance in Inflammatory Bowel Disease: prevalence and risk factors \u2013 A cross-sectional study","volume":"10","author":"Marinelli","year":"2020","journal-title":"Sci Rep"},{"key":"B5","doi-asserted-by":"publisher","first-page":"5354320","DOI":"10.1155\/2019\/5354320","article-title":"Factors influencing disability and quality of life during treatment: A cross-sectional study on IBD patients","volume":"2019","author":"Marinelli","year":"2019","journal-title":"Gastroenterol Res Pract"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1111\/1751-2980.12837","article-title":"Factors associated with disability in patients with ulcerative colitis: A cross-sectional study","volume":"21","author":"Marinelli","year":"2020","journal-title":"J Dig Dis"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2024.11.004","article-title":"Italian validation of the IBD-disk tool for the assessment of disability in inflammatory bowel diseases: A cross-sectional multicenter study","volume":"57","author":"Nardone","year":"2025","journal-title":"Dig Liver Dis"},{"key":"B8","doi-asserted-by":"publisher","first-page":"15251","DOI":"10.1038\/s41598-021-94685-5","article-title":"Sarcopenia, severe anxiety and increased C-reactive protein are associated with severe fatigue in patients with inflammatory bowel diseases","volume":"11","author":"Tasson","year":"2021","journal-title":"Sci Rep"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2025.03.010","article-title":"Adaptation of the European Crohn\u2019s Colitis Organisation quality of care standards to Italy: The Italian Group for the study of inflammatory bowel disease consensus","volume":"57","author":"Fiorino","year":"2025","journal-title":"Dig Liver Dis"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(21)00014-5","article-title":"Prevalence of symptoms of anxiety and depression in patients with inflammatory bowel disease: a systematic review and meta-analysis","volume":"6","author":"Barberio","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1093\/ecco-jcc\/jjab178","article-title":"ECCO guidelines on therapeutics in ulcerative colitis: medical treatment","volume":"16","author":"Raine","year":"2022","journal-title":"J Crohn\u2019s Colitis"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjab010","article-title":"Efficacy of oral, topical, or combined oral and topical 5-aminosalicylates, in ulcerative colitis: systematic review and network meta-analysis","volume":"15","author":"Barberio","year":"2021","journal-title":"J Crohns Colitis"},{"key":"B13","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/S0140-6736(24)01927-5","article-title":"Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies","volume":"405","author":"Rubin","year":"2025","journal-title":"Lancet"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1900750","article-title":"Ustekinumab as induction and maintenance therapy for ulcerative colitis","volume":"381","author":"Sands","year":"2019","journal-title":"N Engl J Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2018.12.009","article-title":"AGA clinical practice guidelines on the management of mild-to-moderate ulcerative colitis","volume":"156","author":"Ko","year":"2019","journal-title":"Gastroenterology"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2022.01.127","article-title":"Use of biologics and small molecule drugs for the management of moderate to severe ulcerative colitis: IG-IBD clinical guidelines based on the GRADE methodology","volume":"54","author":"Macaluso","year":"2022","journal-title":"Digestive liver Dis"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa050516","article-title":"Infliximab for induction and maintenance therapy for ulcerative colitis","volume":"353","author":"Rutgeerts","year":"2005","journal-title":"N Engl J Med"},{"key":"B18","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1056\/NEJMoa1215734","article-title":"Vedolizumab as induction and maintenance therapy for ulcerative colitis","volume":"369","author":"Feagan","year":"2013","journal-title":"N Engl J Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2207940","article-title":"Mirikizumab as induction and maintenance therapy for ulcerative colitis","volume":"388","author":"D\u2019Haens","year":"2023","journal-title":"N Engl J Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(22)00427-7","article-title":"Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial","volume":"8","author":"Feagan","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.12414","article-title":"Risankizumab for ulcerative colitis: two randomized clinical trials","volume":"332","author":"Louis","year":"2024","journal-title":"JAMA"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1606910","article-title":"Tofacitinib as induction and maintenance therapy for ulcerative colitis","volume":"376","author":"Sandborn","year":"2017","journal-title":"N Engl J Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00061-2","article-title":"Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies","volume":"401","author":"Sandborn","year":"2023","journal-title":"Lancet"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2033617","article-title":"Ozanimod as induction and maintenance therapy for ulcerative colitis","volume":"385","author":"Sandborn","year":"2021","journal-title":"N Engl J Med"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00581-5","article-title":"Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials","volume":"399","author":"Danese","year":"2022","journal-title":"Lancet"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00666-8","article-title":"Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b\/3 double-blind, randomised, placebo-controlled trial","volume":"397","author":"Feagan","year":"2021","journal-title":"Lancet"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2021.09.078","article-title":"Breaking through the therapeutic ceiling: what will it take","volume":"162","author":"Raine","year":"2022","journal-title":"Gastroenterology"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2020.10.039","article-title":"Contemporary risk of surgery in patients with ulcerative colitis and Crohn\u2019s disease: a meta-analysis of population-based cohorts","volume":"19","author":"Tsai","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-021-07200-1","article-title":"Systematic review and meta-analysis: risk of hospitalization in patients with ulcerative colitis and Crohn\u2019s disease in population-based cohort studies","volume":"67","author":"Tsai","year":"2022","journal-title":"Dig Dis Sci"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1097\/MIB.0b013e31828029c0","article-title":"Declining risk of colorectal cancer in inflammatory bowel disease: an updated meta-analysis of population-based cohort studies","volume":"19","author":"Lutgens","year":"2013","journal-title":"Inflammation Bowel Dis"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-020-0273-0","article-title":"JAK-STAT pathway targeting for the treatment of inflammatory bowel disease","volume":"17","author":"Salas","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1089099","article-title":"JAK inhibitors: A new dawn for oral therapies in inflammatory bowel diseases","volume":"10","author":"Herrera-deGuise","year":"2023","journal-title":"Front Med (Lausanne)"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjad036","article-title":"Tofacitinib for acute severe ulcerative colitis: A systematic review","volume":"17","author":"Steenholdt","year":"2023","journal-title":"J Crohns Colitis"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2024.07.033","article-title":"Comparative efficacy of biologics and small molecule in ulcerative colitis: A systematic review and network meta-analysis","volume":"23","author":"Shehab","year":"2025","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2022.08.007","article-title":"Efficacy and safety of ivarmacitinib in patients with moderate-to-severe, active, ulcerative colitis: A phase II study","volume":"163","author":"Chen","year":"2022","journal-title":"Gastroenterology"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjy085","article-title":"Peficitinib, an oral Janus kinase inhibitor, in moderate-to-severe ulcerative colitis: results from a randomised, phase 2 study","volume":"12","author":"Sands","year":"2018","journal-title":"J Crohns Colitis"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjad212.0702","article-title":"P572 Evaluation of safety, pharmacokinetics and efficacy of oral treatment with OST-122 in patients with moderate to severe ulcerative colitis: A Phase Ib\/IIa, randomized, double blind, placebo controlled clinical trial","volume":"18","author":"Barreiro-de Acosta","year":"2024","journal-title":"J Crohns Colitis"},{"key":"B38","doi-asserted-by":"publisher","first-page":"2616","DOI":"10.1016\/j.cgh.2022.12.029","article-title":"Oral ritlecitinib and brepocitinib for moderate-to-severe ulcerative colitis: results from a randomized, phase 2b study","volume":"21","author":"Sandborn","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.mucimm.2023.08.001","article-title":"Understanding the molecular mechanisms of anti-trafficking therapies and their clinical relevance in inflammatory bowel disease","volume":"16","author":"Mehandru","year":"2023","journal-title":"Mucosal Immunol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s12950-020-00246-4","article-title":"Ulcerative colitis: understanding its cellular pathology could provide insights into novel therapies","volume":"17","author":"Kaur","year":"2020","journal-title":"J Inflammation"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-016-0603-2","article-title":"Sphingosine-1-phosphate (S1P) and S1P signaling pathway: therapeutic targets in autoimmunity and inflammation","volume":"76","author":"Tsai","year":"2016","journal-title":"Drugs"},{"key":"B42","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1007\/s40265-021-01528-8","article-title":"Targeting sphingosine-1-phosphate signaling in immune-mediated diseases: beyond multiple sclerosis","volume":"81","author":"P\u00e9rez-Jeldres","year":"2021","journal-title":"Drugs"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-021-00574-7","article-title":"Sphingosine 1-phosphate modulation and immune cell trafficking in inflammatory bowel disease","volume":"19","author":"Verstockt","year":"2022","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1905725","article-title":"Vedolizumab versus adalimumab for moderate-to-severe ulcerative colitis","volume":"381","author":"Sands","year":"2019","journal-title":"New Engl J Med"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-022-01762-8","article-title":"Ozanimod: A review in ulcerative colitis","volume":"82","author":"Paik","year":"2022","journal-title":"Drugs"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(22)00022-X","article-title":"AJM300 (carotegrast methyl), an oral antagonist of \u03b14-integrin, as induction therapy for patients with moderately active ulcerative colitis: a multicentre, randomised, double-blind, placebo-controlled, phase 3 study","volume":"7","author":"Matsuoka","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1053\/j.gastro.2018.11.035","article-title":"Efficacy and safety of abrilumab in a randomized, placebo-controlled trial for moderate-to-severe ulcerative colitis","volume":"156","author":"Sandborn","year":"2019","journal-title":"Gastroenterology"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.5217\/ir.2018.00141","article-title":"Efficacy and safety of abrilumab, an \u03b14\u03b27 integrin inhibitor, in Japanese patients with moderate-to-severe ulcerative colitis: a phase II study","volume":"17","author":"Hibi","year":"2019","journal-title":"Intest Res"},{"key":"B49","article-title":"A phase 2 study of MORF-057, an oral \u03b14\u03b27 integrin inhibitor in moderately to severely active ulcerative colitis","author":"Sands","year":"2025","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjab023","article-title":"Long-term safety and efficacy of the anti-MAdCAM-1 monoclonal antibody ontamalimab [SHP647] for the treatment of ulcerative colitis: the open-label study TURANDOT II","volume":"15","author":"Reinisch","year":"2021","journal-title":"J Crohns Colitis"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjad199","article-title":"Efficacy and safety of the anti-mucosal addressin cell adhesion molecule-1 antibody ontamalimab in patients with moderate-to-severe ulcerative colitis or Crohn\u2019s disease","volume":"18","author":"Vermeire","year":"2023","journal-title":"J Crohns Colitis"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1007\/s40495-024-00363-1","article-title":"Efficacy and safety of ontamalimab in treating inflammatory bowel disease: a systematic review and meta-analysis of randomized controlled trials","volume":"10","author":"Awad","year":"2024","journal-title":"Curr Pharmacol Rep"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13227","article-title":"Single-dose of LC51-0255, a selective S1P1 receptor modulator, showed dose-dependent and reversible reduction of absolute lymphocyte count in humans","volume":"15","author":"Won Lee","year":"2022","journal-title":"Clin Transl Sci"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(24)00386-8","article-title":"Tamuzimod in patients with moderately-to-severely active ulcerative colitis: a multicentre, double-blind, randomised, placebo-controlled, phase 2 induction trial","volume":"10","author":"Sands","year":"2025","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B55","doi-asserted-by":"publisher","first-page":"S99","DOI":"10.1053\/j.gastro.2023.03.186","article-title":"A phase II open label study of neihulizumab, an anti-Cd162 (Psgl-1) antibody, in patients with moderate to severe active, anti-Tnf\u03b1 And\/or anti-integrin refractory ulcerative colitis","volume":"164","author":"Rubin","year":"2023","journal-title":"Gastroenterology"},{"key":"B56","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1517\/14712598.2014.858695","article-title":"Targeting TNF-\u03b1 for the treatment of inflammatory bowel disease","volume":"14","author":"Billiet","year":"2014","journal-title":"Expert Opin Biol Ther"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00784","article-title":"Role of TNF\u2013TNF receptor 2 signal in regulatory T cells and its therapeutic implications","volume":"9","author":"Yang","year":"2018","journal-title":"Front Immunol"},{"key":"B58","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1053\/j.gastro.2011.10.032","article-title":"Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis","volume":"142","author":"Sandborn","year":"2012","journal-title":"Gastroenterology"},{"key":"B59","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1053\/j.gastro.2013.06.010","article-title":"Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis","volume":"146","author":"Sandborn","year":"2014","journal-title":"Gastroenterology"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1002\/cmdc.202500258","article-title":"Balinatunfib: A clinical oral small molecule TNF\u03b1 Inhibitor","volume":"20","author":"D\u00f6mling","year":"2025","journal-title":"ChemMedChem"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjac034","article-title":"Interleukin-23 in the pathogenesis of inflammatory bowel disease and implications for therapeutic intervention","volume":"16","author":"Sewell","year":"2022","journal-title":"J Crohns Colitis"},{"key":"B62","unstructured":"Innovent announces phase 2 clinical study of Picankibart (IBI112) in Chinese patients with ulcerative colitis met primary endpoint\n          \n          \n            \n              Biologics\n              I"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2014-308004","article-title":"Tralokinumab for moderate-to-severe UC: a randomised, double-blind, placebo-controlled, phase IIa study","volume":"64","author":"Danese","year":"2015","journal-title":"Gut"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.1084","article-title":"Effect of induction therapy\u00a0with olamkicept vs placebo on clinical response in patients with active ulcerative colitis: A randomized clinical trial","volume":"329","author":"Zhang","year":"2023","journal-title":"JAMA"},{"key":"B65","doi-asserted-by":"publisher","first-page":"i1723","DOI":"10.1093\/ecco-jcc\/jjae190.1090","article-title":"P0916 Lusvertikimab is efficacious in severe ulcerative colitis (UC) patients with high fecal calprotectin (FCP): results from the CoTikiS study","volume":"19","author":"Reinisch","year":"2025","journal-title":"J Crohns Colitis"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjae190.0036","article-title":"OP36 Lusvertikimab, a first-in-class IL7 receptor antagonist, in moderate to severe Ulcerative Colitis: results of a multicenter, randomized, placebo-controlled phase II study","volume":"19","author":"Bourreille","year":"2025","journal-title":"J Crohns Colitis"},{"key":"B67","doi-asserted-by":"publisher","first-page":"i2015","DOI":"10.1093\/ecco-jcc\/jjae190.1271","article-title":"P1097 Phase 1\/2 study to assess safety, tolerability, and efficacy of XmAb942 (anti-TL1A) in healthy participants and participants with ulcerative colitis","volume":"19","author":"Hung","year":"2025","journal-title":"J Crohns Colitis"},{"key":"B68","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.3390\/cells12141889","article-title":"The melanocortin system in inflammatory bowel diseases: insights into its mechanisms and therapeutic potentials","volume":"12","author":"Gravina","year":"2023","journal-title":"Cells"},{"key":"B69","doi-asserted-by":"publisher","first-page":"i576","DOI":"10.1093\/ecco-jcc\/jjae190.0349","article-title":"P0175 A new blocker of endothelial dysfunction ameliorates colitis independently of IL-10 by regulating both barrier function and the recruitment of immune cells","volume":"19","author":"Park","year":"2025","journal-title":"J Crohns Colitis"},{"key":"B70","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1053\/j.gastro.2023.03.230","article-title":"Low-dose IL-2 for the treatment of moderate to severe ulcerative colitis","volume":"165","author":"Allegretti","year":"2023","journal-title":"Gastroenterology"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1097\/MIB.0000000000000492","article-title":"Tumor necrosis factor-like cytokine TL1A and its receptors DR3 and DcR3: important new factors in mucosal homeostasis and inflammation","volume":"21","author":"Siakavellas","year":"2015","journal-title":"Inflammation Bowel Dis"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2314076","article-title":"Phase 2 trial of anti-TL1A monoclonal antibody Tulisokibart for ulcerative colitis","volume":"391","author":"Sands","year":"2024","journal-title":"N Engl J Med"},{"key":"B73","doi-asserted-by":"publisher","first-page":"S1046","DOI":"10.14309\/01.ajg.0001035184.00247.3f","article-title":"S1454 long-term efficacy and safety of intravenous (IV) tulisokibart in patients with ulcerative colitis (UC): results from the open-label extension (OLE) period of the phase 2 ARTEMIS-UC study","volume":"119","author":"Ma","year":"2024","journal-title":"Off J Am Coll Gastroenterol | ACG"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2024-332504","article-title":"Targeting TL1A and DR3: the new frontier of anti-cytokine therapy in IBD","volume":"74","author":"Bamias","year":"2025","journal-title":"Gut"},{"key":"B75","doi-asserted-by":"publisher","first-page":"2324","DOI":"10.1016\/j.cgh.2021.06.011","article-title":"Anti-TL1A antibody PF-06480605 safety and efficacy for ulcerative colitis: A phase 2a single-arm study","volume":"19","author":"Danese","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(25)00129-3","article-title":"Anti-TL1A antibody, afimkibart, in moderately-to-severely active ulcerative colitis (TUSCANY-2): a multicentre, double-blind, treat-through, multi-dose, randomised, placebo-controlled, phase 2b trial","volume":"10","author":"Danese","year":"2025","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B77","doi-asserted-by":"publisher","first-page":"i1802","DOI":"10.1093\/ecco-jcc\/jjad212.1128","article-title":"P998 Phase 2 basket design study evaluating the efficacy and safety of an anti-TL1A antibody (TEV-48574) in moderate to severe ulcerative colitis or Crohn\u2019s Disease (RELIEVE UCCD)","volume":"18","author":"Reinisch","year":"2024","journal-title":"J Crohns Colitis"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjae190.0039B","article-title":"OP41 Duvakitug (TEV-48574), an anti-TL1a monoclonal antibody, demonstrates efficacy and favourable safety as an induction treatment in adults with moderately to severely active ulcerative colitis: Results from a phase 2b, randomised, double-blind, placebo-controlled, dose-ranging, basket trial (RELIEVE UCCD)","volume":"19","author":"Reinisch","year":"2025","journal-title":"J Crohns Colitis"},{"key":"B79","doi-asserted-by":"publisher","first-page":"jjaf074","DOI":"10.1093\/ecco-jcc\/jjaf074","article-title":"Obefazimod in patients with moderate-to-severely active ulcerative colitis: efficacy and safety analysis from the 96-week open-label maintenance phase 2b study","volume":"19","author":"Vermeire","year":"2025","journal-title":"J Crohns Colitis"},{"key":"B80","doi-asserted-by":"publisher","first-page":"2526","DOI":"10.1016\/j.cgh.2019.12.032","article-title":"Effects of apremilast, an oral inhibitor of phosphodiesterase 4, in a randomized trial of patients with active ulcerative colitis","volume":"18","author":"Danese","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B81","doi-asserted-by":"publisher","first-page":"i1763","DOI":"10.1093\/ecco-jcc\/jjae190.1116","article-title":"P0942 Orismilast for the treatment of moderate to severe Ulcerative Colitis: Analysis of preliminary data from UCORIS, a phase 2a, open-label, single-arm exploratory clinical trial","volume":"19","author":"Velte Honor\u00e9","year":"2025","journal-title":"J Crohns Colitis"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.18818","article-title":"Pharmacology of orismilast, a potent and selective PDE4 inhibitor","volume":"37","author":"Silverberg","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-016-4276-1","article-title":"Ameliorating active ulcerative colitis via an orally available toll-like receptor-9 modifier: A prospective open-label, multicenter phase II trial","volume":"61","author":"Dotan","year":"2016","journal-title":"Dig Dis Sci"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izz094","article-title":"The safety, tolerability, and pharmacokinetics profile of BT-11, an oral, gut-restricted lanthionine synthetase C-like 2 agonist investigational new drug for inflammatory bowel disease: A randomized, double-blind, placebo-controlled phase I clinical trial","volume":"26","author":"Leber","year":"2020","journal-title":"Inflammation Bowel Dis"},{"key":"B85","doi-asserted-by":"publisher","first-page":"S","DOI":"10.1016\/S0016-5085(25)01316-2","article-title":"650: Oral Omilancor Treatment Outperforms Anti-Tl1a Therapeutics In Ibd","volume":"169","author":"Tubau-Juni","year":"2025","journal-title":"Gastroenterology"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-009-9323-7","article-title":"Oral administration of OKT3 monoclonal antibody to human subjects induces a dose-dependent immunologic effect in T cells and dendritic cells","volume":"30","author":"Ilan","year":"2010","journal-title":"J Clin Immunol"},{"key":"B87","doi-asserted-by":"publisher","first-page":"otz009","DOI":"10.1093\/crocol\/otz009","article-title":"Immunologic alterations associated with oral delivery of anti-CD3 (OKT3) monoclonal antibodies in patients with moderate-to-severe ulcerative colitis","volume":"1","author":"Boden","year":"2019","journal-title":"Crohns Colitis 360"},{"key":"B88","article-title":"Dual targeting of TNF and IL-23 by a bispecific antibody in ulcerative colitis","volume":"11","author":"Atreya","year":"2025","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.17305\/bjbms.2022.7348","article-title":"Inhibition of IRAK 1\/4 alleviates colitis by inhibiting TLR4\/NF-\u03baB pathway and protecting the intestinal barrier","volume":"22","author":"Yan","year":"2022","journal-title":"Bosn J Basic Med Sci"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2024.06.036","article-title":"The future of clinical trials in inflammatory bowel disease","volume":"23","author":"Ma","year":"2025","journal-title":"Clin Gastroenterol Hepatol"}],"container-title":["Frontiers in Gastroenterology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fgstr.2026.1747118\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T05:25:58Z","timestamp":1769750758000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fgstr.2026.1747118\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,30]]},"references-count":90,"alternative-id":["10.3389\/fgstr.2026.1747118"],"URL":"https:\/\/doi.org\/10.3389\/fgstr.2026.1747118","relation":{},"ISSN":["2813-1169"],"issn-type":[{"value":"2813-1169","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,30]]},"article-number":"1747118"}}